Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Digital health tools

Topic: Health services, long-term care and technology

Purpose To evaluate the risk of developing Alzheimer disease (AD) or other dementia in patients diagnosed with open-angle glaucoma (OAG) in a nationally representative longitudinal sample of elderly persons. Methods This retrospective cohort study (January 1, 1994-December 31, 2007) used Medicare 5% claims data. We identified beneficiaries aged 68+ years who had at least two claims with diagnoses of OAG and no Alzheimer or other dementia in 1994, using a 3-year look-back period between 1991 and 1993 (n = 63,235) and beneficiaries matched on age, sex, race, and Charlson index without a diagnosis of OAG throughout the observational period (n = 63,235), using propensity score matching. Using a Cox Proportional Hazards model, we analyzed time to AD diagnosis and time to AD or other dementia diagnosis. Results Elderly individuals diagnosed with OAG did not have an increased rate of AD and other dementia diagnosis compared to those without OAG during a 14-year follow-up period, even after controlling for relevant covariates present at baseline. Conclusions Individuals aged 68+ years diagnosed with OAG have a decreased rate of AD or other dementia diagnosis compared to control patients without an OAG diagnosis. Although OAG and AD are both age-related neurodegenerative diseases, our findings do not support a positive association.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ou, Y., Grossman, D. S., Lee, P. P., & Sloan, F. A. (2012). Glaucoma, Alzheimer disease and other dementia: a longitudinal analysis. Ophthalmic epidemiology. https://doi.org/10.3109/09286586.2011.649228

Vancouver

Ou Y, Grossman DS, Lee PP, Sloan FA. Glaucoma, Alzheimer disease and other dementia: a longitudinal analysis. Ophthalmic epidemiology. 2012. doi:10.3109/09286586.2011.649228. PMID: 22978529.

BibTeX

@article{ou2012-22978529,
  author  = {Ou, Y. and Grossman, D. S. and Lee, P. P. and Sloan, F. A.},
  title   = {{Glaucoma, Alzheimer disease and other dementia: a longitudinal analysis}},
  journal = {Ophthalmic epidemiology},
  year    = {2012},
  doi     = {10.3109/09286586.2011.649228},
  pmid    = {22978529},
  url     = {https://doi.org/10.3109/09286586.2011.649228}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Study details

How this study scored 64/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 4 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here left out, no data; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multi-centre collaboration left out, no data; Indexed in PubMed 2 of 2; Free to read 0 of 2. 37 of the 58 points it could be judged on, which is 64 of 100. Total 64 of 100.37 of the 58 points we could judge = 64 of 100

Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 37 of the 58 points we could judge it on, which is 64 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Ophthalmic epidemiology)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2012 — within 20 year(s) of the newest study here
Sample size 4 / 4 63,235 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here — / 6 Not yet checked against this library's citation graph — left out of this score
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multi-centre collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 22978529)
Free to read 0 / 2 Behind a paywall — scores zero
Points 37 / 58 Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 37 of the 58 points we could judge it on is 64 out of 100.
Total 64 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Related studies in Digital health tools

Also tagged “costs”

265 studies in the library carry the topic tag “costs”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 265 tagged studies.

Similar studies

More on Digital health tools

See all studies in Digital health tools →